Live Breaking News & Updates on Solebury Strategic Communications|Page 1

Stay updated with breaking news from Solebury strategic communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bexion Pharmaceuticals, Inc. to Present at BIO International Convention 2024

Bexion Pharmaceuticals, Inc. to Present at BIO International Convention 2024
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

San Diego , United States , William Windham , Joyce Laviscount , Prnewswire Bexion Pharmaceuticals Inc , Bexion Pharmaceuticals , Bexion Pharmaceuticals Inc , International Convention , Solebury Strategic Communications , Biotechnology Innovation Organization , Innovation Organization , Chief Executive ,

Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Review of Strategic Alternatives

PRINCETON, NJ / ACCESSWIRE / May 22, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced ....

Jack Yauch , Company Or Sonnet , Sonnet Biotherapeutics Holdings Inc , Solebury Strategic Communications , Securities Exchange , Exchange Commission , Chardan Capital Markets , Fully Human Albumin Binding , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Ihr Portfolio ,

American Oncology Network Announces Voluntary Delisting From Nasdaq

FORT MYERS, Fla., May 21, 2024 American Oncology Network , a rapidly growing network of community-based oncology practices, announced today its decision to voluntarily delist its Class A common. ....

United States , Todd Schonherz , Securities Exchange , Group Inc , Committee The Special Of Board , American Oncology Network , Company Nasdaq , Company Annual Report On Form , Solebury Strategic Communications , Exchange Commission , Oncology Network , Nasdaq Capital Market , Special Committee , Securities Exchange Act , Exchange Act , Chief Executive Officer , Annual Report ,

Sonnet BioTherapeutics : Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

. ....

United States , Pankaj Mohan , Jack Yauch , Robert Wenham , Richard Kenney , Sonnet Biotherapeutics Holdings Inc , Exchange Commission , Solebury Strategic Communications , Oncology At Moffitt Cancer Center , Company Or Sonnet , Roche Group , Securities Exchange , Fully Human Albumin Binding , Secreted Protein Acidic , Safety Review Committees , Chief Medical , Response Evaluation Criteria , Solid Tumors , Moffitt Cancer Center , Lead Principal Investigator , Sonnet Founder , Chief Executive , Secreted Protein , Programed Death Ligand , Securities Act , Securities Exchange Act ,

Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10 ....

United States , Pankaj Mohan , Jack Yauch , Robert Wenham , Richard Kenney , Sonnet Biotherapeutics Holdings Inc , Solebury Strategic Communications , Exchange Commission , Oncology At Moffitt Cancer Center , Company Or Sonnet , Roche Group , Securities Exchange , Fully Human Albumin Binding , Secreted Protein Acidic , Safety Review Committees , Chief Medical , Response Evaluation Criteria , Solid Tumors , Moffitt Cancer Center , Lead Principal Investigator , Sonnet Founder , Chief Executive , Secreted Protein , Programed Death Ligand , Securities Act , Securities Exchange Act ,